cyrilzakka/clinical-trials huggingface dataset:
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.


Eligibility Criteria:
Inclusion Criteria:

* Participants will be 18 years of age or older
* History of gynecologic cancer.
* Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy
* Female participants of child-bearing potential must have a negative urine or serum pregnancy test at the time of the screening visit.
* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific procedures.
* Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician.

Exclusion Criteria

* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study.
* Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
* Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subjects safety or successful participation in the study.
* Unwilling or unable to provide informed consent
The Influence of Acute Hyperglycaemia on Brain in T1D

The study is going to include 20 adolescents, 5-10 years after onset of T1D, aged 12-20 years, on insulin pump. The participants are going to have MRI of the head in euglycaemic and hyperglycaemic state. During both MRI, the participants are going to preform Flanker test, Tower of London test and Spatial memory test. The investigators are going to evaluate the response of inflammation markers and oxidative stress marekers in blood during hypreglycaemia.

The study is going to include 20 patientswith T1D. The group of patients is going to be homogeneous. The inclusion criteria are going to be: duration of T1D approximately 5 - 10 years, age between 10 and 24 years, without associated clinical complications of T1D, similar value of HbA1c and BMI within the normal range (depending on the percentile for age and sex), treatment with an insulin pump. Only the patients who are going to give written consent to participate in the form "Declaration of conscious and free consent" are going to be included.

All selected clinical data to determine the phenotypic characteristics of the patient will be obtained from available medical records or. at their regular outpatient reading.

After 12-hour fasting overnight, the patients will undergo 2h hyperglycaemic clamp.

During hyperglycemia a sample of venous blood for the evaluation of oxidative stress, inflammatory response and the expression of non-coding RNA is going to be drawn.

Subjects will have 1H-MRS in hyperglycaemic and euglycaemic state and evaluation of executive function (using psychological tests) is going to be preformed. For 1H-MRS, the MRI of the head in order to obtain anatomical data is going to be preformed at first .

Eligibility Criteria:
Inclusion Criteria:

* T1D on insulin pump, no diabetic complication, normal BMI and blood pressure

Exclusion Criteria:

-
Evaluation of Ultrasound for Detecting Hip Impingement

Patients are being asked to participate in this study because a previous research MRI of their hips showed that the shape of the head of their thigh bone may indicate FAI of the hip. We have already collected cartilage imaging data and data on how the hip joint moves on people with painful/symptomatic FAI and people with normal hip function. We would now like to compare the motion of the hip joint to those with painful FAI using ultrasound.

Hip impingement is thought to be a leading cause of hip osteoarthritis, and occurs due to deformities in the hip joint. However some individuals have these deformities but do not exhibit symptoms. Using the standard magnetic resonance imaging and clinical tests it is not clear which deformities will cause degeneration, requiring surgical intervention. We propose to evaluate the deformity and impingement between the femur and acetabulum using dynamic ultrasound imaging. Ultrasound does not involve radiation and can acquire video of the hip joint and is thus suitable for such diagnostic purposes. In this pilot study we will evaluate the feasibility of ultrasound in diagnosing hip impingement.

Eligibility Criteria:
Inclusion Criteria:

Surgical group:

* Hip pain longer than 6 months referred to the groin/lateral aspect of the hip
* Positive Impingement Sign

Plain radiographs:

* Absence of arthritis (Tonnis Grade 0 or 1)
* Absence of dysplasia (center edge \>25 degrees) on anterior-posterior radiograph
* α-angle greater than 60 degrees on MRI.

Exclusion Criteria:

* Patients who don't meet inclusion criteria
* Control group: subjects with hip pain or with alpha angle \> 50 degrees on MRI
The Effect of Different Types of Resin Cements on the Color Stability of Two Different Types of Ceramic Veneers

Aim of the study was to evaluate the color stability of lithium disilicate ceramic veneers and zirconia reinforced lithium silicate ceramic veneers by using two different types of resin cements including light cured and dual cured cements.


Eligibility Criteria:
Inclusion Criteria:

* Good oral hygiene with compliance to perform strict oral hygiene measures (periodontal screening index 0-1).
* Slight malposition.
* Teeth with spacing.
* Teeth with discoloration

Exclusion Criteria:

* Advanced periodontitis, gingivitis, or recession.
* Abutments with subgingival restorations or root caries.
* Parafunctional habits.
* Undergoing orthodontic treatment.
* Presence of orthodontic appliance.
* Obvious dentition malalignment.
* Mandibular prognathism.
* Maxillary retrognathism.
* Smokers.
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES

To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with DES.

This trial is a prospective, randomized, multi-center, open label, noninferiority trial. Patients undergoing PCI with DES will be eligible. After successful PCI with DES, all eligible patients will be randomized either to clopidogrel monotherapy or to aspirin plus P2Y12 antagonist following 3-month of DAPT.

Eligibility Criteria:
Inclusion Criteria:

* Subject must be at least 20 years of age.
* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
* Patients undergoing successful PCI

Exclusion Criteria:

* Hemodynamic instability or cardiogenic shock
* Active bleeding
* Known hypersensitivity or contraindication to study medications
* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
* Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
* DES implantation within 12 months before index procedure
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects

The purpose of this study is to characterise the metabolism, excretion and pharmacokinetics of a single oral dose of \[14C\] AZD1236 in healthy male subjects.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* Non-smokers

Exclusion Criteria:

* Subjects who are exposed to radiation exposure as part of their occupation
* Subjects exposed to radiation levels above background of \>5 mSv in last year, \>10 mSv over last 5 years or a cumulative total of \> 1 mSv per year of life
* A history or presence of conditions known to interfere with the absorption, distribution, metabolism or excretion for drugs eg. haematological, gastrointestinal, hepatic or renal disease etc
Bipolar Disorder Study for Men and Women

A Placebo Controlled Study Evaluating Efficacy and Safety of Medication in Patients with Bipolar Disorder


Eligibility Criteria:
Inclusion Criteria:

* Patients must provide written and informed consent
* Diagnosis of Bipolar I Disorder and currently depressed for minimum of the previous 8 weeks
* Patients must have been hospitalized for mood disorder or incarceration with or without formal charges as the result of mania related behavior

Exclusion Criteria:

* Patients must not be suicidal
* Patients must not have a history or non-response to antidepressant treatment
* Patients must not have a clinical history of substance dependence in the past year or abuse within the 4 weeks prior to study entry
* Patients must not have had epilepsy or hypothyroidism
Testing the Contribution of Orbitofrontal Cortex Networks to Decision-making

This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making.

This study will combine functional magnetic resonance imaging (fMRI), non-invasive transcranial magnetic stimulation (TMS), olfactory stimuli, and a devaluation task to define the specific contributions of orbitofrontal cortex (OFC) networks in outcome-guided behavior. We will use network-targeted TMS to modulate activity within anterior OFC and posterior OFC networks, examining if they have different contributions to decision-making. This is a randomized, between-subjects design.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 40 years old
* Right-handed
* Fluent English speakers

Exclusion Criteria:

* History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.)
* History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, substance use disorder, etc.)
* Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.)
* Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.)
* Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.)
* Smell or taste dysfunction
* History of significant allergies requiring hospitalization for treatment
* History of severe asthma requiring hospitalization for treatment
* Habitual smoking
* History of eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, etc.)
* Dieting or fasting
* Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)
* Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.)
* History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers
* Claustrophobia
* Pregnancy
* Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.)
* Use of medications that increase the likelihood of seizures (e.g., bupropion SR, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)
* History of surgical procedures performed on the brain or spinal cord
* History of severe head trauma followed by loss of consciousness
* History of fainting spells or syncope
* Hearing problems or tinnitus
Supportive-Expressive and Emotion-Focused Treatment for Depression

This study will explore the mechanisms of change that are activated when individuals receive a treatment that targets their weakness and the mechanisms activated when the treatment capitalize on their strength. Patients will be assigned to one of two types of psychotherapies in treating people with a major depression disorder, expressive-supportive vs. emotion-focused treatment. Their ability to benefit from treatment based on their pre-treatment levels of insight and emotional processing will be examined. This is a four-month protocol, with a 2 year follow up period.

One hundred and twenty-four patients suffering from major depressive disorder will be randomized to participate in 16 sessions of either supportive-expressive therapy or emotion-focused therapy. The two treatments are theorized to differ in their main mechanism of change: supportive-expressive therapy places emphasis on insight as its main mechanism of change, and emotion-focused therapy places emphasis on emotional processing as its main mechanism of change. Both can serve as strength- or weakness-focused treatments, based on the patient's baseline levels of insight and emotional processing. Importantly, this study will employ multiple complementary methods, which will include session-by-session self-report questionnaires from both patient and therapist, as well as interdisciplinary measures based on hormonal and acoustic measures, cognitive tasks, clinician interviews, and behavioral coding systems to complement the self-report measures. In addition, prior the beginning of treatment patients will complete diaries via mobile survey application. The findings will contribute to the research on personalized mechanisms of change and can help clinicians focus on more efficient treatment delivery, adapted to given subpopulations of patients, according to their strengths and weaknesses. If a mechanism most likely to stimulate change for a subpopulation is identified, a corresponding treatment can be chosen that is most likely to activate that particular mechanism and by that improve the rate of patients' respondent to treatment.

Eligibility Criteria:
Inclusion Criteria:

* Meeting major depressive disorder diagnostic criteria using the structured clinical interviews for Diagnostic and Statistical Manual of Mental Disorders-5 and scoring more than 14 on the 17-item Hamilton rating scale for depression at two evaluations (one week apart) (Hamilton, 1967).
* If on medication, patients' dosage must be stable for at least three months prior to entering the study, and they must be willing to maintain stable dosage for the duration of treatment
* Age between 18 and 65
* Hebrew language fluency
* Provision of written informed consent.

Exclusion Criteria:

* Current risk of suicide or self-harm
* current substance abuse disorders
* current or past schizophrenia or psychosis, bipolar disorder, or severe eating disorder requiring medical monitoring
* history of organic mental disease
* currently in psychotherapy
Polar Body Removal Before ICSI for Oocyte Activation in Previous Fertilization Failure Cases

Cases which undergone ICSI before with failure of fertilization will do another ICSI cycle with removal of the polar body just before the ICSI procedure and sperm injection at the site of polar body removal. This study group will be evaluated with another group with the classic ICSI procedure

Patients with previous fertilization failure will be divided into 2 groups:

Group 1 (control): Will undergo classic ICSI procedure in half the MII oocyte of the same case.

Group 2 (study group): The other half of the MII oocyte of the same case will undergo:

1. Polar body removal.
2. ICSI procedure with injection of the spermatozoon in the same zona opening (done by laser for polar body removal).

Results: Will be collected with evaluation of number of 2PN zygotes, Day 1, Day 2, Day 3, Day 5 embryos in all the cases.

Eligibility Criteria:
Inclusion Criteria:

* previous fertilization failure
* previous fertilization arrest

Exclusion Criteria:

* NO MII oocyte
* Refusal of the procedure by the couple
Metabolic Adaptations to High-fat Diet

The purpose of this study is to understand how the body's response after a meal is influenced by insulin and sugar in the blood. The primary question this study seeks to address is what is the effect of reduced insulin sensitivity on postprandial metabolic flexibility to an oral glucose tolerance test. We will recruit 50 adults (ages 20-45; 50% female) who are otherwise healthy (no known clinical diagnosis) into our non-randomized crossover trial to determine the effect of changes in insulin sensitivity on metabolic response to feeding. Insulin sensitivity will be decreased using a three-day high-fat diet (HFD) with extra calories. Whole-body metabolism will be measured during a standard 75-gram oral glucose tolerance test (OGTT). Metabolic response to feeding (e.g. OGTT) will be compared before and after the HFD and compared with the control diet to understand the effect of decreased insulin sensitivity on the metabolic response to feeding. The role of biological sex as a moderator of the effect of increased insulin resistance on postprandial metabolic flexibility will also be investigated


Eligibility Criteria:
Inclusion Criteria:

* Males or Females between the ages of 20 and 45 years
* Body mass index (BMI) of 18.5-29.9 kg/m2
* Low risk for medical complications as determined by physical activity readiness questionnaire (PARQ).
* Low risk for food insecurity via the Hunger Vital Sign screener

Exclusion Criteria:

* Currently taking any antioxidant supplementation, prescription non-steroidal anti- inflammatory drugs, antibiotics, steroids, probiotics, medications for management of cholesterol, diabetes, body weight/obesity, or are undergoing transgender hormone therapy.
* Currently pregnant (verified by urine pregnancy test)
* Any history of disordered eating (i.e., anorexia nervosa, bulimia nervosa, binge eating disorder, etc.) or high risk for disordered eating via validated questionnaire (SCOFF)
* Any history of gastrointestinal diseases (i.e., gastroesophageal reflux disease, irritable bowel syndrome, Celiac disease, Crohn's disease, or lactose intolerance)
* Allergies to wheat or gluten, milk, soy, tree nuts (e.g., almonds, walnuts, pecans), or peanuts.
* Followed a ketogenic diet within the last three months
* Instructed by a medical provided to avoid a high-fat diet due to cardiovascular disease risk.
* Cardiorespiratory fitness (VO2max) greater than the 90th percentile for age and sex
Pre Transplantation Melanoma

Melanoma incidence is increase in global population and number of transplantation also. However immunosuppressor increase recurrence risk of melanoma.

There are more and more cases of eligible patients to transplant with an antecedent of melanoma. There is no guideline yet.

Main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.


Eligibility Criteria:
Inclusion Criteria:

* patient with an antecedent of melanoma before transplantation
* Not opposite to participate

Exclusion Criteria:

* Under the age of 18
* patient under Guardianship
* patient not affiliated with a health system
Role of A2A Receptor in Hypercholesterolemic Patients

Hypercholesterolemia promotes chronic inflammation, endothelial dysfunction, atherosclerosis and is a major risk factor for cardiovascular disease (CVD). Treatment with lipid-lowering drugs (statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C). Nevertheless, a better understanding of the effects of hypercholesterolemia on the cardiovascular and immune systems could help identify all the mechanisms responsible for the excess risk of CVD in hypercholesterolemic patients and develop better prevention and treatment strategies.

Adenosine via A2A receptors (A2AR) plays a crucial role in the regulation of the cardiovascular and immune systems.

In this project, the investigators wish :

* To study whether the expression and function of A2AR in PBMCs are altered in human hypercholesterolemia, using as a study model a larger cohort of patients with hypercholesterolemia of increasing level and severity: polygenic form, heterozygous genetic form and homozygous genetic form in comparison with healthy subjects with normal cholesterol levels.
* To study whether A2AR expression and function in PBMCs are associated with blood levels of LDL-C and homocysteine and with the inflammatory status of patients.
* To assess whether the cholesterol-lowering therapies currently used to reduce LDL-C levels and thus the risk of CVD in hypercholesterolemic patients have an impact on possible alterations of A2AR expression and function in PBMCs.


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects aged 18-80 years
* For the group of hypercholesterolemic patients :

  * LDL-cholesterol level \>1.9 g/L with or without treatment to make the diagnosis of hypercholesterolemia (laboratory test less than 12 months old at inclusion)
* For the healthy group :

  ● No cholesterol-modifying therapy.
* Subject not having hypercholesterolemia (biological assessment less than 12 months old at inclusion with LDL-cholesterol level \< 1.9 g/L) and not taking cholesterol-lowering treatment.
* Subjects who are affiliated or beneficiaries of a social security plan
* Subject agreeing to participate in the study and having signed an informed consent

Exclusion Criteria:

* Protected person, as defined by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code: pregnant or breastfeeding woman, person deprived of liberty by judicial decision, adult person unable to give consent.
* Person who does not understand the French language
Ticagrelor and Adenosine

Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative nucleoside transporter (ENT). This mechanism can contribute to the beneficial effects and to the side effects (dyspnea) of ticagrelor in patients with an acute myocardial infarction. In the current research proposal, we aim to investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.


Eligibility Criteria:
Inclusion Criteria:

* Male sex
* Age 18-40 years
* Healthy
* Written informed consent

Exclusion Criteria:

* Smoking
* Hypertension (Blood pressure \>140 mmHg and/or \>90 mmHg - SBP/DBP-)
* Diabetes Mellitus (fasting glucose \> 7.0 mmol/L or random \> 11.0 mmol/L)
* History of any cardiovascular disease
* History of chronic obstructive pulmonary disease (COPD) or asthma
* Bleeding tendency
* Concomitant use of medication
* Renal dysfunction (MDRD \< 60 ml/min)
* Liver enzyme abnormalities (ALAT \> twice upper limit of normality)
* Thrombocytopenia (\<150\*109/ml)
* Second/third degree AV-block on electrocardiography